Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.78 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.78 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.78 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.60 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | SELP | P16109 | 1/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7558073 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL7564857 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL12171709 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL7559085 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL7557265 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL25439708 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL7563562 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL7558400 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL20499894 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL7557249 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002072068-A2 | LIPIDS, LIPID COMPOSITIONS, LIPOSOMES, AND LIPOPLEXES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-09-19 | — | — | WO | claimed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4655402-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | Providence Therapeutics Holdings Inc. (CA) | 2025-12-03 | — | — | EP | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-03-06 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023044333-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2002072068-A2 | LIPIDS, LIPID COMPOSITIONS, LIPOSOMES, AND LIPOPLEXES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-09-19 | — | — | WO | disclosed |
| EP-0685234-B1 | DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER | NIPPON SHINYAKU CO LTD (JP) | 2000-05-10 | — | — | EP | disclosed |
| US-6020317-A | Glycerol derivative, device and pharmaceutical composition | NIPPON SHINYAKU CO. LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0685457-B1 | GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU CO LTD (JP) | 1999-12-15 | — | — | EP | disclosed |
| US-5705188-A | LIPID MIXTURE, ANTITUMOR AGENTS | NIPPON SHINYAKU COMPANY, LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
| EP-0685457-A1 | GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
| EP-0685234-A1 | DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-5045338-A | Ester imides, acylated aminoalcohol derivatives | NABISCO BRANDS, INC. (US) | 1991-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | PRKCA 3726/4885PRKCE 4209/4885PRKCQ 3047/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | PRKCA 2857/4885PRKCE 2833/4885PRKCQ 2746/4885 |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | SGMS1, SGMS2, ABCB4 | PRKCA 2742/4885PRKCE 3225/4885PRKCQ 2566/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | PRKCA 2481/4885PRKCE 2260/4885PRKCQ 1238/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | PRKCA 3726/4885PRKCE 4209/4885PRKCQ 3047/4885 |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | PRKCA 2433/4885PRKCE 3279/4885PRKCQ 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.